What is the difference between MGF and Tesamorelin?

MGF: MGF (Mechano Growth Factor) is a splice variant of IGF-1 produced locally in muscle tissue in response to mechanical loading (exercise, especially eccentric loading). Unlike circulating IGF-1 which is produced primarily by the liver, MGF is generated within the muscle itself and acts locally to activate satellite cells (muscle stem cells) — the cells responsible for muscle repair, growth, and adaptation. It is considered the primary local anabolic signal generated by resistance training. Tesamorelin: Tesamorelin is an FDA-approved synthetic analog of growth hormone-releasing hormone (GHRH). Approved in 2010 as Egrifta, it is the only GHRH peptide with an approved clinical indication — reduction of excess visceral abdominal fat in people with HIV-associated lipodystrophy. It has the most robust human trial evidence of any growth hormone secretagogue, including dedicated studies on visceral fat and liver fat. Both are in the Performance & Growth Hormone category but differ in mechanism, dosing, and research evidence — see the full comparison.

Can you take MGF and Tesamorelin together?

There is no specific, well-documented interaction rule for combining MGF and Tesamorelin in the aggregated research reviewed. Combining peptides should only be considered under professional supervision. This is not medical advice.

Which is better researched, MGF or Tesamorelin?

MGF is currently preclinical only and Tesamorelin is fda-approved. "Better researched" depends on your research goal — review each profile's cited sources.

Performance & Growth Hormone · Comparison

MGF vs Tesamorelin

A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

MGF

Preclinical only

MGF (Mechano Growth Factor) is a splice variant of IGF-1 produced locally in muscle tissue in response to mechanical loading (exercise, especially eccentric loading). Unlike circulating IGF-1 which is produced primarily by the liver, MGF is generated within the muscle itself and acts locally to activate satellite cells (muscle stem cells) — the cells responsible for muscle repair, growth, and adaptation. It is considered the primary local anabolic signal generated by resistance training.

Full profile

Tesamorelin

FDA-approved

Tesamorelin is an FDA-approved synthetic analog of growth hormone-releasing hormone (GHRH). Approved in 2010 as Egrifta, it is the only GHRH peptide with an approved clinical indication — reduction of excess visceral abdominal fat in people with HIV-associated lipodystrophy. It has the most robust human trial evidence of any growth hormone secretagogue, including dedicated studies on visceral fat and liver fat.

Full profile

	MGF	Tesamorelin
Category	Performance & Growth Hormone	Performance & Growth Hormone
Also known as	Mechano Growth Factor, IGF-1Ec, Insulin-like Growth Factor splice variant	Egrifta, Egrifta SV, TH9507, GHRH analog
Evidence	Preclinical only	FDA-approved
Dosing range	100mcg–300mcg mcg, Post-workout (within 30–60 minutes of training), 3–4x weekly	1.28mg–2mg mg, once daily (subcutaneous)
Administration	Intramuscular injection (into worked muscle — critical for local effect), Subcutaneous injection (produces more systemic distribution)	Subcutaneous injection (abdomen, with site rotation)
Key side effects	Localized muscle swelling at injection site (normal response), Hypoglycemia (less pronounced than IGF-1 DES but present), Very short half-life means side effects are brief, Potential overuse injury if post-workout injection is used consistently without adequate recovery	Injection site reactions (erythema, pruritus), Peripheral edema, Arthralgia (joint pain), Myalgia
Cited sources	3 references	5 references

Key differences

Evidence level differs: MGF is preclinical only, while Tesamorelin is fda-approved.
Administration: MGF — Intramuscular injection (into worked muscle — critical for local effect), Subcutaneous injection (produces more systemic distribution); Tesamorelin — Subcutaneous injection (abdomen, with site rotation).
Dosing units differ: MGF is dosed in mcg, Tesamorelin in mg — they operate at different scales.
Frequency: MGF is typically Post-workout (within 30–60 minutes of training), 3–4x weekly; Tesamorelin is once daily (subcutaneous).
Research depth: this profile cites 3 sources for MGF vs 5 for Tesamorelin.

How each works

MGF

MGF is encoded by the IGF-1 gene but produced via alternative splicing that generates a unique 49-amino acid C-terminal E-peptide (Ec peptide). The Ec peptide has distinct biological activity from the IGF-1 domain — it directly activates satellite cell proliferation through a receptor pathway separate from the standard IGF-1R. Studies in rodents show that local MGF injection produces significant muscle hypertrophy in the injected limb without systemic IGF-1 elevation. MGF expression spikes within 30 minutes of resistance exercise and declines over 24–48 hours — aligning precisely with the post-exercise anabolic window.

Tesamorelin

Tesamorelin stimulates pulsatile growth hormone (GH) release from the pituitary, raising serum IGF-1 and preferentially reducing visceral adipose tissue (VAT). FDA-registration trials (Falutz et al., NEJM 2007; JAIDS 2010) showed ~15% VAT reduction versus placebo over 26 weeks. Later randomized trials (Stanley et al., JAMA 2014; Lancet HIV 2019) extended the evidence to liver fat, showing meaningful reductions in hepatic fat fraction and attenuated fibrosis progression in HIV-associated NAFLD.

Read the full MGF profile Read the full Tesamorelin profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.